Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | GFER | P55789 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2385374 | 0.90 | KDM4E (0.41) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL2383613 | 0.88 | ALDH1A1 (0.41) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL2381110 | 0.87 | MAPK1 (0.43) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL6281112 | 0.87 | KDM4E (0.41) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL2382552 | 0.87 | ALDH1A1 (0.41) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL3444475 | 0.87 | ACHE (0.46) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL2383709 | 0.87 | KDM4E (0.41) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL2385245 | 0.87 | MAOB (0.41) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL3445384 | 0.86 | ACHE (0.45) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 | |
| SCHEMBL2383697 | 0.86 | KDM4E (0.46) | KDM4EHPGDHSD17B10SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524857-B2 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | SANOFI-AVENTIS (FR) | 2009-04-28 | — | — | US | claimed |
| US-7160895-B2 | Use of pyridoindolone derivatives for the preparation of medicinal products | SANOFI-AVENTIS (FR) | 2007-01-09 | — | — | US | claimed |
| EP-1385513-B1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI AVENTIS (FR) | 2006-09-06 | — | — | EP | claimed |
| EP-1385512-B1 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | SANOFI AVENTIS (FR) | 2005-12-28 | — | — | EP | claimed |
| US-20050272760-A1 | Use of pyridoindolone derivatives for the preparation of medicinal products | SANOFI-AVENTIS (FR) | 2005-12-08 | — | — | US | claimed |
| US-6967203-B2 | Use of pyridoindolone derivatives for preparing anticancer medicines | SANOFI-AVENTIS (FR) | 2005-11-22 | — | — | US | claimed |
| US-20040122027-A1 | Use of pyridoindolone derivatives for preparing anticancer medicines | SANOFI (FR) | 2004-06-24 | — | — | US | claimed |
| US-20040122036-A1 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | SANOFI (FR) | 2004-06-24 | — | — | US | claimed |
| EP-1385512-A2 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | claimed |
| EP-1385513-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | claimed |
| WO-2002087575-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | claimed |
| WO-2002087574-A2 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | claimed |
| US-7524857-B2 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | SANOFI-AVENTIS (FR) | 2009-04-28 | — | — | US | disclosed |
| US-7160895-B2 | Use of pyridoindolone derivatives for the preparation of medicinal products | SANOFI-AVENTIS (FR) | 2007-01-09 | — | — | US | disclosed |
| EP-1385513-B1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI AVENTIS (FR) | 2006-09-06 | — | — | EP | disclosed |
| EP-1385512-B1 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | SANOFI AVENTIS (FR) | 2005-12-28 | — | — | EP | disclosed |
| EP-1385512-A2 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385513-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | Sanofi-Aventis (FR) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002087575-A1 | PHARMACEUTICAL COMBINATIONS BASED ON PYRIDOINDOLONE DERIVATIVES AND ANTICANCER AGENTS | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002087574-A2 | USE OF PYRIDOINDOLONE DERIVATIVES FOR PREPARING ANTICANCER MEDICINES | SANOFI-SYNTHELABO (FR) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272760-A1 | Use of pyridoindolone derivatives for the preparation of medicinal products | DPYD, PNPO, ENTPD5 | KDM4E 3484/4885HPGD 6/4885HSD17B10 1238/4885 |
| US-20040122036-A1 | Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents | DPYD, DHFR, PNPO | KDM4E 3327/4885HPGD 27/4885HSD17B10 763/4885 |
| US-20040122027-A1 | Use of pyridoindolone derivatives for preparing anticancer medicines | DPYD, PNPO, TYMP | KDM4E 3148/4885HPGD 15/4885HSD17B10 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.